Bristol-myers Squibb
PARIS, October 21, 2011 -
Hepatitis B is one of the most common infectious diseases in the world, with 350 million people worldwide being chronically infected [1] - this compares with 33 million people living with HIV infection [2]- yet there remains a lack of reliable resources for hepatitis B patientsand caregivers
PATH B - "Patients and Professionals Acting Together for Hepatitis B" (www.pathb.com) - is a new programme that provides information and tools to guide patients through their journey with chronic hepatitis B from diagnosis to long-term disease management
A pioneering educational resource, designed to improve the lives of people living with chronic hepatitis B, was launched today at an annual conference organised by Bristol-Myers Squibb in Hong Kong where 26 patient advocacy groups from 14 countries and regions gathered to discuss viral hepatitis.
PARIS, June 20, 2011 -
European Commission approves NULOJIX
(belatacept), in combination with corticosteroids and a
mycophenolic acid and an interleukin-2 receptor antagonist at
induction, for prophylaxis of graft rejection in adult patients
receiving a kidney transplant
First new mode of action for prevention of graft rejection
in kidney transplantation in a decade
Similar rates of graft and patient survival with better
preservation of renal function seen at one year and maintained
through three years vs.
PARIS, June 10, 2011 -
Five-year follow-up results were presented today from a Phase 3
randomised, open-label, dose-optimisation study of SPRYCEL(R) (dasatinib) in
Philadelphia chromosome-positive (Ph+) chronic-phase chronic myeloid
leukaemia(CP-CML) adult patients resistant or intolerant to imatinib
mesylate.
PARIS, December 8, 2010 - Bristol-Myers Squibb today announced that SPRYCEL(R) (dasatinib) 100mg
once daily received Marketing Authorization from the European Commission for
the treatment of adult patients with newly diagnosed Philadelphia chromosome
positive (Ph+) Chronic Myelogenous Leukaemia in Chronic Phase (CML-CP).
PRINCETON, New Jersey and TOKYO, December 6, 2010 - Bristol-Myers Squibb Company (www.bms.com) (NYSE:BMY) and Otsuka
Pharmaceutical Co., Ltd.
